- Home
- SPMA vs SCLXW Comparison
SPMA vs SCLXW Comparison
Compare SPMA & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPMA | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | 34 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPMA | SCLXW |
|---|---|---|
| Price | $25.07 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 4.0K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $24.70 | $0.05 |
| 52 Week High | $25.60 | $0.64 |
Technical Indicators
Market Signals| Indicator | SPMA | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 55.68 |
| Support Level | $24.99 | $0.11 |
| Resistance Level | $25.31 | $0.21 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 50.02 | 78.12 |
Price Performance
Historical ComparisonAbout SPMA Sound Point Meridian Capital Inc.
Sound Point Meridian Capital Inc is a closed-end management investment company. The Company's primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.